Fenretinide activates caspases and induces apoptosis in gliomas.

The synthetic retinoid fenretinide (N-[4-hydroxyphenyl] retinamide or 4HPR) has been shown to not only inhibit cell growth but also to induce apoptosis in a variety of malignant cell lines. It is being tested presently for its potential as a chemopreventive agent against several cancers. A related retinoid, 13-cis-retinoic acid (cRA), has been shown to have activity against gliomas in vitro as well as in a recent clinical study. The present study aimed at assessing the activity of fenretinide against glioma cells in vitro and comparing it with that of cRA at pharmacologically relevant doses. We hypothesized that the ability of fenretinide to induce apoptosis would make it more potent against gliomas than cRA. Four glioma cell lines (D54, U251, U87MG, and EFC-2) were treated with fenretinide (1-100 microM) and showed dose- and time-dependent induction of cell death. At pharmacologically relevant doses, fenretinide was more active against glioma cells than cRA because of its ability to induce apoptosis. Flow cytometric studies using D54 cells demonstrated no significant changes in the cell cycle distribution compared with untreated control, but a sub-G1 fraction consistent with apoptosis was detected. Terminal deoxynucleotidyl transferase-mediated nick end labeling assay indicated that the apoptotic fraction was cell cycle nonspecific. Fenretinide treatment resulted in cleavage of poly ADP-ribose polymerase, indicating an activation of the caspase 3. Immunofluorescence studies using the nuclear stain 4',6-diamidine-2'-phenylindole dihydrochloride showed nuclear condensation and an apoptotic morphology. Hence, this study demonstrates that, at clinically relevant doses, fenretinide is a potent inducer of apoptosis in gliomas acting via the caspase pathway. We also show that at clinically achievable doses, fenretinide has more activity against gliomas than comparable doses of cRA. The favorable side effect profile seen in previous clinical studies and the in vitro activity against gliomas demonstrated in this study suggest that fenretinide could be a promising therapeutic agent against gliomas.

[1]  T. Hsieh,et al.  Regulation of G1/S transition and induction of apoptosis in HL‐60 leukemia cells by fenretinide (4HPR) , 1998, International journal of cancer.

[2]  W. Hong,et al.  Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  R. Dodge,et al.  Fenretinide-Induced Apoptosis of Human Head and Neck Squamous Carcinoma Cell Lines , 1998, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[4]  M. Pfahl,et al.  Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation , 1997, Molecular and cellular biology.

[5]  L. Mariani,et al.  Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale, Design, Methodology, Organization, Data Management, Statistics and Accrual , 1997, Tumori.

[6]  C. Brock,et al.  Current perspectives in gliomas , 1997, Medical oncology.

[7]  A. Arslantaş,et al.  Management of glioblastoma multiforme: with special reference to recurrence , 1997, Clinical Neurology and Neurosurgery.

[8]  F. Zwas,et al.  Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. , 1997, American journal of clinical oncology.

[9]  R. Fine,et al.  PROSTATE CANCER CELLS , 2015 .

[10]  W. Yung,et al.  Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  T. Hsieh,et al.  Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. , 1996, Biochemical and biophysical research communications.

[12]  R. Lotan.  Retinoids in cancer chemoprevention , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  F. Zunino,et al.  Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression , 1996, International journal of cancer.

[14]  U. Veronesi,et al.  Chemoprevention of breast cancer with fenretinide. , 1996, IARC scientific publications.

[15]  R. Lotan.  Retinoids and apoptosis: implications for cancer chemoprevention and therapy. , 1995, Journal of the National Cancer Institute.

[16]  F. Formelli,et al.  Risks and Benefits of Retinoids in the Chemoprevention of Cancer , 1995, Drug safety.

[17]  Alberto Costa,et al.  Retinoids in Cancer Chemoprevention , 1995 .

[18]  V. Pistoia,et al.  Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. , 1995, Cancer research.

[19]  U. Veronesi,et al.  Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. , 1995, Annals of the New York Academy of Sciences.

[20]  W. Hong,et al.  Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implications for chemoprevention , 1995, Journal of cellular biochemistry. Supplement.

[21]  W. Yung.  New approaches to molecular therapy of brain tumors. , 1994, Current opinion in neurology.

[22]  M. Igawa,et al.  N‐(4‐hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells , 1994, The Prostate.

[23]  M. Costantini,et al.  Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. , 1994, Journal of the National Cancer Institute.

[24]  T. Man.  Solid tumours--chemoprevention with retinoids. , 1994, Leukemia.

[25]  V. Steele,et al.  Clinical development plan: N-(4-hydroxyphenyl)retinamide. , 1994, Journal of cellular biochemistry. Supplement.

[26]  S. Ménard,et al.  N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. , 1993, Cancer research.

[27]  S. Jabłońska,et al.  Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. , 1993, Cancer letters.

[28]  M. Clerici,et al.  Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Pienta,et al.  Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. , 1993, Cancer research.

[30]  P. V. D. van de Kerkhof,et al.  Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). , 1990, Journal of hepatology.

[31]  M. Filla,et al.  Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[32]  R. Mehta,et al.  Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer. , 1989, Cancer letters.

[33]  W Malone,et al.  Tolerability of the synthetic retinoid Fenretinide (HPR). , 1989, European journal of cancer & clinical oncology.

[34]  E. Hodak,et al.  Adverse Effects of Retinoids , 1988, Medical toxicology and adverse drug experience.

[35]  C. Marth,et al.  Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells. , 1985, Journal of the National Cancer Institute.

[36]  J. Paulson,et al.  Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide. , 1985, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[37]  M. Sporn,et al.  N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. , 1979, Cancer research.

[38]  J. B. Mark,et al.  Chemotherapy of malignant brain tumors. , 1966, Geriatrics.